Abstract
In this controlled study of 46 patients with myofascial pain syndrome, we investigated the effects of infrared (IR) laser application to trigger points and medical treatment on pain reduction and serotonin and its degradation products. Retaining double-blind trial principles, the patients were randomly assigned to two groups. The treatment group received IR laser treatment, whereas the control group received sham laser. However, both groups received medical treatment. In the treatment group, laser was applied once a day for 10 consecutive days at a dose of 1.44 J/cm2. The effect of the laser treatment on pain was evaluated by visual analog scale. Urinary excretion of 5-hydroxy indole acetic acid (5-HIAA) and serotonin + 5-hydroxy tryptophan (5-HT+5-HTP) was studied by column chromatography. At the end of the treatment, there was a statistically significant difference between the VAS values of the treatment and control groups. The 24-h urinary excretion of the 5-HIAA and 5-HT+5-HTP was significantly higher in the laser treatment group than in the placebo group. In conclusion, IR laser is an effective modality in the treatment of MPS which increases an important mediator of pain inhibition, serotonin.
Similar content being viewed by others
References
Travel JG, Simons DG (1992) Myofascial pain and dysfunction: the trigger point manual. Vol 2. Williams and Wilkins, Baltimore, pp 541–558
Bennet RM (1993) The fibromyalgia syndrome. Myofascial pain and the chronic fatigue syndrome. In: Kelley H, Ruddy S (eds) Textbook of rheumatology. Fourth edn. Saunders, Philadelphia, pp 471–483
Simons DG (1990) Muscular syndromes. In: Friction JR (ed) Advances in pain research and therapy. Raven, New York, pp 1–41
King JC, Goddard MJ (1994) Pain rehabilitation, chronic pain syndrome and myofascial pain. Arch Phys Med Rehabil 75:9–14
Snyder-Mackler L, Barry AJ, Perkins AI, Soucek MD (1989) Effect of He-Ne laser irradiation on skin resistance and pain in patients with trigger points in the neck and back. Phys Ther 69:336–341
Goldenberg DL (1994) Soft tissue. In: Klippel JH, Dieppe PA (eds) Rheumatology. Hilo, Colchester, pp 5–6
Casisi JE, Sypert GW (1993) Pain, disability and psychological functioning in chronic low back pain subgroups: myofascial versus herniated disk syndrome. Neurosurg 33:379–385
Gecherelli F, Altafini L, Lo Castro G, Avilla A, Ambrosio F, Giron GP (1989) Diode laser in cervical myofascial pain: a double blind study versus placebo. Clin J Pain 5:301–304
Walker J (1983) Relief from chronic pain by low power laser irradiation. Neurosci Lett 43:339–344
Jorgen HH, Thoroe U (1990) Low-power laser biostimulation of chronic orofacial pain: a double-blind placebo controlled cross-over study in 40 patients. Pain 9:169–179
Tietz NW (1986) Endocrinology. Textbook of clinical chemistry. Saunders, Philadelphia, pp 1155–1160
Krsnich-Shriwise S (1997) Fibromyalgia syndrome and overview. Phys Ther 77:68–75
Udenfriend S, Titus E, Weissbach H (1955) The identification of 5-hydroxy-3-indoleacetic acid in normal urine and method for its assay. J Biol Chem 216:499–505
Beckerman H, Bie RA, Bouther LM, Cuyper HJ, Oosttendorp RAB (1992) The efficacy of laser therapy for musculoskeletal and skin disorders: a criteria-based meta-analysis of randomized clinical trials. Phys Ther 72: 483–491
Cambier DC, Vanderstraeten G (1997) Low-level laser therapy: the experience in Flanders. Eur J Phys Med Rehabil 7:102–105
Olavi A, Pekka R, Pertti K, Pekka P (1989) Effect of infrared laser therapy at treated and nontreated trigger points. Acupuncture Electrother Res 14:9–14
Synder-Mackler L, Bork CE, Bourben B, Trumbore D (1986) Effect of He-Ne laser on musculoskeletal trigger points. Phys Ther 66:087–1090
Waylonis GW, Wilke S, O’Toole D, Waylonis DA, Waylonis DB (1988) Chronic myofascial pain management by low-output laser therapy. Arch Phys Med Rehabil 69:1017–1020
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ceylan, Y., Hizmetli, S. & Siliğ, Y. The effects of infrared laser and medical treatments on pain and serotonin degradation products in patients with myofascial pain syndrome. A controlled trial. Rheumatol Int 24, 260–263 (2004). https://doi.org/10.1007/s00296-003-0348-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00296-003-0348-6